#1 Clinical Trials Search in Europe

Bedaquiline

Bedaquiline is a novel antibiotic being studied in clinical trials for the treatment of multidrug-resistant tuberculosis (MDR-TB). This article summarizes key findings from several clinical trials evaluating the safety, efficacy, and pharmacokinetics of bedaquiline in adults and children with MDR-TB.

Table of Contents

What is Bedaquiline?

Bedaquiline is a medication used to treat certain types of tuberculosis (TB). It is also known by other names such as TMC207, R207910, JNJ-16175328, and Sirturo[1][2][3][4]. This drug is particularly important because it is effective against forms of TB that are resistant to other common treatments.

How Bedaquiline Works

Bedaquiline works by targeting the bacteria that cause tuberculosis. It interferes with the bacteria’s ability to produce energy, which ultimately leads to their death. This unique mechanism of action makes bedaquiline effective against TB strains that have become resistant to other antibiotics[1].

Conditions Treated with Bedaquiline

Bedaquiline is primarily used to treat:

  • Multidrug-Resistant Tuberculosis (MDR-TB): This is a form of TB that is resistant to at least two of the most powerful first-line anti-TB drugs[1][2].
  • Rifampicin-Resistant Tuberculosis (RR-TB): This is TB that is resistant to rifampicin, one of the main drugs used to treat TB[5].
  • Pulmonary Tuberculosis: This refers to TB that affects the lungs[6].

It’s important to note that bedaquiline is typically used in combination with other TB medications, known as a background regimen (BR), to create a comprehensive treatment plan[1][2].

Dosage and Administration

The dosage of bedaquiline can vary depending on the patient’s age, weight, and specific condition. However, a common dosing regimen for adults is as follows:

  • Loading dose: 400 mg once daily for the first 2 weeks
  • Maintenance dose: 200 mg three times per week (with at least 48 hours between doses) for the next 22 weeks[1][5]

For children and adolescents, the dosage is typically adjusted based on body weight[2]. Bedaquiline is usually taken orally in tablet form, but research is being conducted on different formulations, including crushed tablets for those who have difficulty swallowing[3].

Efficacy of Bedaquiline

Clinical trials have shown that bedaquiline is effective in treating MDR-TB and RR-TB. The drug’s efficacy is often measured by:

  • Sputum Culture Conversion: This refers to when a patient’s sputum (mucus coughed up from the lungs) no longer contains live TB bacteria. Studies have shown that bedaquiline can help achieve this faster than standard treatments[1][5].
  • Early Bactericidal Activity (EBA): This measures how quickly the drug kills TB bacteria in the first few days of treatment[6].

Potential Side Effects

Like all medications, bedaquiline can cause side effects. Common side effects may include:

  • Nausea
  • Joint pain
  • Headache
  • Changes in heart rhythm (QT prolongation)[1][2]

It’s important to report any side effects to your healthcare provider. They will monitor you closely, especially for any heart-related issues.

Special Considerations

There are several important factors to consider when using bedaquiline:

  • Drug Interactions: Bedaquiline can interact with other medications. For example, studies have been conducted to understand how it interacts with drugs like rifampicin and clarithromycin[7][4].
  • Liver Function: Patients with moderate liver impairment may need special monitoring when taking bedaquiline[8].
  • HIV Co-infection: Some studies have included patients with both TB and HIV, indicating that bedaquiline can be used in this population with appropriate monitoring[9].

Ongoing Research

Research on bedaquiline is ongoing. Current areas of study include:

  • Use in children and adolescents[2][9]
  • Different formulations (e.g., crushed tablets)[3]
  • Long-term safety and efficacy[5]
  • Interactions with other medications[7][4]

These ongoing studies aim to improve our understanding of bedaquiline and optimize its use in treating drug-resistant tuberculosis.

Aspect Details
Drug Name Bedaquiline (also known as TMC207, Sirturo)
Indication Treatment of multidrug-resistant tuberculosis (MDR-TB)
Administration Oral tablets, typically with a loading dose followed by a maintenance dose
Key Findings – Effective in achieving sputum culture conversion – Shows promise in both adults and children with MDR-TB – Being studied in various combinations with other TB medications
Safety Considerations – Monitoring for heart rhythm abnormalities (QT prolongation) – Common side effects include nausea, joint pain, headache
Ongoing Research – Optimal dosing for different age groups – Drug-drug interactions – Long-term efficacy and safety

FAQ

  • What is bedaquiline? Bedaquiline is a new antibiotic medication being studied for the treatment of multidrug-resistant tuberculosis (MDR-TB). It works differently from other TB drugs and shows promise in treating TB that is resistant to standard medications.
  • How is bedaquiline given to patients? Bedaquiline is typically given orally as tablets. The dosing regimen often involves a higher loading dose for the first 2 weeks, followed by a lower maintenance dose for several more weeks. The exact dosing depends on factors like the patient's age and weight.
  • What are some of the main side effects of bedaquiline? Common side effects being monitored in clinical trials include nausea, joint pain, and headache. Researchers are also closely watching for any heart rhythm abnormalities, as bedaquiline can affect the electrical activity of the heart in some patients.
  • Is bedaquiline effective against drug-resistant TB? Early clinical trial results suggest bedaquiline is effective in treating MDR-TB when combined with other TB medications. Studies have shown it can help patients achieve negative TB cultures faster than standard treatments alone.
  • Is bedaquiline being studied in children with TB? Yes, there are ongoing clinical trials evaluating the safety, proper dosing, and effectiveness of bedaquiline in infants, children and adolescents with MDR-TB. Researchers are working to determine the right doses for different pediatric age groups.

Ongoing Clinical Trials on Bedaquiline

  • Study on the Effectiveness of Clofazimine and Drug Combination for Treating Mycobacterium abscessus Lung Disease in Adult Patients

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study of bedaquiline, pretomanid, linezolid and moxifloxacin combination treatment for patients with multidrug-resistant tuberculosis in France

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    France

Glossary

  • Multidrug-resistant tuberculosis (MDR-TB): A form of tuberculosis that is resistant to at least two of the most powerful first-line TB drugs, isoniazid and rifampicin. It is more difficult to treat than regular TB.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and eliminated. PK studies help determine proper dosing.
  • Sputum culture conversion: When a patient's sputum (mucus coughed up from the lungs) changes from testing positive for TB bacteria to testing negative, indicating the treatment is working.
  • Background regimen (BR): The combination of other TB medications given alongside the study drug (bedaquiline) in clinical trials.
  • QT interval: A measurement of the heart's electrical cycle. Prolongation of the QT interval can indicate an increased risk of abnormal heart rhythms.
  • Colony forming units (CFU): A measure of viable bacterial cells in a sample. Used to quantify the number of TB bacteria in sputum samples.
  • Bioequivalence: When two formulations of a drug have the same rate and extent of absorption in the body, meaning they should have the same therapeutic effect.
  • Open-label study: A type of clinical trial where both the researchers and participants know which treatment is being given.

References

  1. https://clinicaltrials.gov/study/NCT02365623
  2. https://clinicaltrials.gov/study/NCT02354014
  3. https://clinicaltrials.gov/study/NCT03032367
  4. https://clinicaltrials.gov/study/NCT03800550
  5. https://clinicaltrials.gov/study/NCT05824871
  6. https://clinicaltrials.gov/study/NCT01215110
  7. https://clinicaltrials.gov/study/NCT02216331
  8. https://clinicaltrials.gov/study/NCT01012284
  9. https://clinicaltrials.gov/study/NCT02906007